XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders
3 Months Ended
Mar. 31, 2023
Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders  
Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders

Note 4. Net Income per Share

Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP.

For the three months ended March 31, 2023, options to purchase 1,403,859 shares of stock with a weighted-average exercise price of $34.96 per share were excluded from the computation of diluted net income per share because their effect would be anti-dilutive.

For the three months ended March 31, 2022, options to purchase 706,740 shares of stock with a weighted-average exercise price of $34.74 per share were excluded from the computation of diluted net income per share because their effect would be anti-dilutive.

The following table provides the calculation of basic and diluted net income per share for each of the periods presented:

Three Months Ended

March 31, 

2023

2022

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

Net income

$

26,032

$

24,253

Denominator:

Weighted-average shares outstanding — basic

 

48,000

48,138

Net effect of dilutive securities:

Incremental shares from equity awards

 

3,970

3,841

Weighted-average shares outstanding — diluted

 

51,970

 

51,979

Net income per share — basic

$

0.54

$

0.50

Net income per share — diluted

$

0.50

$

0.47